Silexion Therapeutics (SLXN) Earnings Date & Reports

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SLXN is expected to report earnings to rise 194.00% to -1519 cents per share on November 18

Silexion Therapeutics SLXN Stock Earnings Reports

Q3'26

Est.

$-15.20

Q2'26

Beat

by $7.93

Q4'25

Missed

by $1.15

Q3'25

Missed

by $2.63

The last earnings report on August 14 showed earnings per share of -517 cents, beating the estimate of -1310 cents. With 845.19K shares outstanding, the current market capitalization sits at 1.38M.

View a ticker or compare two or three

SLXN

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for SLXN